| Name | Title | Contact Details |
|---|
Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.
The Fisher Wallace Stimulator® is a wearable neurostimulation device cleared by the FDA to treat depression, anxiety and insomnia. During each 20-minute treatment session, the device gently stimulates the brain to produce serotonin and other neurochemi...
Cedarburg Pharmaceuticals delivers unsurpassed value in the development and manufacturing of commercial and clinical APIs. We believe value is more than just price. Value means making your life simpler. Our process development, scale-up, commercial
Talley Group | Specialists in pressure relieving mattresses and cushions, electric bed frames, negative pressure wound therapy, IPC, and infection control
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.